Latest news

Events and Conferences

Interphex Week Tokyo 2026 organises show floor around manufacturing, packaging, inspection and digital production technologies

Interphex Week Tokyo 2026 will take place from 20-22 May at Makuhari Messe, bringing together six specialised exhibitions and a concurrent regenerative medicine expo covering pharmaceutical and cosmetics manufacturing, ingredients, laboratory and quality technologies, digital transformation, biopharma, and...
Commercial

Bio-Rad launches PTC Harmony 96 and PTC Harmony Deepwell thermal cyclers

Bio-Rad Laboratories has launched the PTC Harmony Thermal Cycler line, designed to offer broader access to optimised workflows for PCR applications such as sequencing, cloning, and genotyping. PTC Harmony 96 and PTC Harmony Deepwell are the latest additions to...
Funding & Finance

Evotec announces chief financial officer transition

Evotec SE has announced that chief financial officer (CFO) Paul Hitchin will step down on 30 April 2026 for personal reasons unrelated to the company. The supervisory board has accepted Mr Hitchin’s decision and expressed deep appreciation for his...
CDMO strategy

PCI Pharma Services announces US$1 billion expansion of US sterile fill-finish and drug-device delivery combination capabilities

PCI Pharma Services, a world-leading integrated global contract development and manufacturing organisation (CDMO) focused on innovative biologic and small molecule therapies, has announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug...
Discovery

ImmunoForge to accelerate central nervous system drug development with innovative blood-brain barrier shuttle platform

ImmunoForge, a clinical-stage biopharmaceutical company specialising in treatments for rare and muscular diseases, is poised to redefine central nervous system (CNS) drug delivery with its proprietary LMT15 Platform, a next-generation blood-brain barrier (BBB) shuttle technology. The LMT15 Platform is based on...
Phase 3

Novo Nordisk to seek oral sickle cell therapy approval after phase 3 success

A phase 3 trial of Novo Nordisk’s once-daily tablet has met both co-primary endpoints, reducing vaso-occlusive crises (VOC) and increasing haemoglobin (Hb) response in patients with sickle cell disease (SCD). In the pivotal hHibiscus trial (NCT04624659), the etavopivat arm...
Events and Conferences

AI Drug Discovery & Development Summit (AIDDD)

27-29 October 2026 Boston Marriott Copley Place, Boston, USA The AI Drug Discovery & Development Summit (AIDDD) is the meeting place for the innovators redefining how medicines are discovered and developed. Bringing together leaders from pharma, biotech, AI, and academia, the...
Events and Conferences

Global Drug Delivery and Formulation (DDF) Summit

18-20 May Berlin, Germany The Global Drug Delivery and Formulation (DDF) Summit is Europe’s premier gathering for professionals at the forefront of pharmaceutical development and drug delivery science. Now in its 17th year, the Summit has earned a reputation for delivering exceptionally...
Events and Conferences

Chemspec Europe reveals new details about 2026 conference programme

6–7 May 2026 Koln, Germany Chemspec Europe has unveiled further details of its highly anticipated conference programme, offering attendees fresh insight into the key themes, sessions and new interactive formats shaping this year’s event. Taking place on 6–7...
Phase 1-2

Dayspring Pharma announces phase 2 trial of CG2001 foam met primary endpoint in Chinese adult men with androgenetic alopecia

Dayspring Pharma has announced top-line data from its phase 2 clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful results, with a favourable...
Funding & Finance

PlaqueTec secures $5 million financing to advance drug discovery

PlaqueTec, a medtech company pioneering intracoronary liquid biopsy to identify inflammatory drivers of cardiovascular disease (CVD), has raised $5 million. The oversubscribed financing round was funded entirely by the company’s existing investor base. The investment will support the continued build-out...
Commercial

Expanded antibody portfolio enhances detection of biologics and therapeutics for bioanalytical applications

Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, has extended its range of recombinant monoclonal anti-idiotypic antibodies, with the introduction of eight antibodies specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isatuximab (Sarclisa),...
Phase 3

AstraZeneca to seek accelerated approval of Ultomirisin in immunoglobulin A nephropathy on phase 3 data

AstraZeneca plans to seek accelerated approval of Ultomirisin kidney disease after the drug showed benefit after just 34 weeks, meeting its first primary endpoint. In the phase 3 I can study (NCT06291376), patients with immunoglobulin A nephropathy (IgAN) treated...
Phase 1-2

Tenvie doses first subject in phase 1 TNV108 trial for peripheral neuropathies

Tenvie Therapeutics has dosed the first participant in its phase 1 clinical trial of TNV108 to treat peripheral neuropathies. The trial will assess the tolerability and safety of single and multiple ascending TNV108 doses in healthy volunteers. As a first-in-human...
Phase 3

Roche reports phase 3 study results for myelin oligodendrocyte glycoprotein antibody-associated disease

Roche has reported new findings from the phase 3 meteoroid trial of Enspryng (satralizumab) in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The double-blind, randomised, multi-centre, placebo-controlled trial revealed that Enspryng reduced the risk of a...
Discovery

IRBM reports progress in drug discovery for Zika virus

IRBM, a leader in early drug discovery research, recently announced a major scientific breakthrough with the discovery of a new and potent allosteric inhibitor targeting the Zika virus (ZIKV) protease (NS2B-NS3). The results, published in Nature Communications, demonstrate the...
Discovery

Sofetabart mipitecan receives ‘Breakthrough Therapy’ designation for the treatment of certain patients with platinum-resistant ovarian cancer

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine,...
Phase 1-2

Preliminary AMT-191 phase 1/2a data shows sustained increases in α-Gal A enzyme activity in patients with Fabry Disease

uniQure has announced updated preliminary safety and exploratory efficacy data from 11 patients in its phase 1/2a trial of AMT-191, an investigational AAV gene therapy for the treatment of Fabry disease. The updated data was presented at the WORLDSymposium in San...
Phase 3

Positive phase 3 topline results for oral infigratinib

BridgeBio Pharma, a biopharmaceutical company focused on developing medicines for genetic conditions, has announced positive topline results from Propel 3, the global phase 3 pivotal study of oral infigratinib in children living with achondroplasia. Achondroplasia is the most common...
Discovery

FDA removes barriers to cell, gene therapy development

The FDA has said it will reduce the regulatory requirements on the manufacturing of cell and gene therapies (CGTs) in order to make it easier for developers to bring them to market. Specifically, the US regulator wants to amend...
Discovery

IRBM reports progress in drug discovery for Zika virus

IRBM, a leader in early drug discovery research, recently announced a major scientific breakthrough with the discovery of a new and potent allosteric inhibitor targeting the Zika virus (ZIKV) protease (NS2B-NS3). The results, published in Nature Communications, demonstrate the...
IND-enabling

Preclinical data published in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5)

Lexicon Pharmaceuticals has announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The paper, titled ‘Acyl-CoA Synthetase 5 knockout and inhibitors protect against diet-induced obesity in mice...
Pharma in Healthcare

FDA grants approval for a gene therapy to treat rare genetic disease

The FDA has issued its stamp of approval to a new, cell-based option to treat Wiskott-Aldrich syndrome (WAS), marking the first therapy of its kind for the rare disease and making Italy’s Fondazione Telethon the first nonprofit to usher...
Discovery

New results on NanoCas – an efficient ultracompact extrahepatic gene editor

Mammoth Biosciences, a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, has announced new preclinical research, published on the preprint server bioRxiv, that establishes proof-of-concept of NanoCasâ„¢, the first ultracompact...
Phase 1-2

Positive longer-term phase 1 data of Nexiguran Ziclumeran (nex-z) in patients with Transthyretin Amyloidosis with cardiomyopathy

Intellia Therapeutics, a leading clinical-stage gene editing company focused on revolutionising medicine with CRISPR-based therapies, has announced positive follow-up data from the ongoing phase 1 clinical trial of its investigational product nexiguran ziclumeran (nex-z) in patients with transthyretin (ATTR) amyloidosis...
- Advertisement -spot_img
- Advertisement -
DDF Summit ad
- Advertisement -
EPO Summit ad
- Advertisement -
ILMAC ad
- Advertisement -

MOST POPULAR POSTS

Drug Discovery & Development (DDD) is dedicated to advancing scientific innovations into active medical solutions. Its aim is to accelerate breakthroughs in medicine, addressing human disease and improving global health outcomes.

Menu

© Web design by Social Media Services 2026. All rights reserved.